Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1396-1404

  Dees, Clara ^a   Zerr, Pawel ^a   Tomcik, Michal ^a   Beyer, Christian ^a   Horn, Angelika ^a   Akhmetshina, Alfiya ^a   Palumbo, Katrin ^a   Reich, Nicole ^a   Zwerina, Jochen ^a   Sticherling, Michael ^a   Mattson, Mark P ^b   Distler, Oliver ^c   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR DAPT; MESSENGER RNA; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MALE; MOUSE; NONHUMAN; NOTCH INTRACELLULAR DOMAIN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; REMISSION; SKIN; SKIN FIBROSIS; SUBCUTANEOUS TISSUE; SYSTEMIC SCLEROSIS; TIGHT SKIN;

ADULT; ANIMALS; BLEOMYCIN; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MICE; MIDDLE AGED; RECEPTORS, NOTCH; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 79955567838     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30254     Document Type: Article

References (32)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67. (Pubitemid 46348510)
3. Chung L, Krishnan E, Chakravarty EF,. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford) 2007; 46: 1808-13. (Pubitemid 350168296)
4. Charles C, Clements P, Furst DE,. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683-91. (Pubitemid 43728250)
5. Kim R, Meyer KC,. Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2008; 2: 319-38.
6. Swigris JJ, Brown KK, Make BJ, Wamboldt FS,. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med 2008; 102: 1675-80.
7. Morgan T, Bridges C,. Sex-linked inheritance in Drosophila. Carnegie Institution of Washington, Pub. 237. Washington (DC): Gibson Brothers; 1916.
8. Kopan R, Ilagan MX,. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-33.
9. Kageyama R, Ohtsuka T, Kobayashi T,. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 2007; 134: 1243-51. (Pubitemid 46710809)
10. Fortini ME,. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009; 16: 633-47.
11. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, et al. Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J Clin Invest 2005; 115: 3166-76. (Pubitemid 41567581)
12. Roy M, Pear WS, Aster JC,. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007; 17: 52-9. (Pubitemid 46109291)
13. Purow B,. Notch inhibitors as a new tool in the war on cancer: a pathway to watch. Curr Pharm Biotechnol 2009; 10: 154-60.
14. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
15. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214-22. (Pubitemid 351948641)
16. Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF III, Gay RE, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A 2005; 102: 2892-7. (Pubitemid 40299887)
17. Chigurupati S, Arumugam TV, Son TG, Lathia JD, Jameel S, Mughal MR, et al. Involvement of Notch signaling in wound healing. PLoS One 2007; 2: e1167.
18. Teachey DT, Seif AE, Brown VI, Bruno M, Bunte RM, Chang YJ, et al. Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood 2008; 111: 705-14.
19. Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B, Simel EJ, et al. Notch-1 regulates NF-γ B activity in hemopoietic progenitor cells. J Immunol 2001; 167: 4458-67. (Pubitemid 32954323)
20. Green MC, Sweet HO, Bunker LE,. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493-512.
21. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
22. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22. (Pubitemid 46106205)
23. Woessner JF Jr., The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-7.
24. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62. (Pubitemid 29171935)
25. Kavian N, Servettaz A, Mongaret C, Wang A, Nicco C, Chereau C, et al. Targeting ADAM-17/Notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 2010; 62: 3477-87.
26. Amsen D, Antov A, Flavell RA,. The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol 2009; 9: 116-24.
27. Real PJ, Ferrando AA,. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 2009; 23: 1374-7.
28. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L,. Rational targeting of Notch signaling in cancer. Oncogene 2008; 27: 5124-31.
29. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-8.
30. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, et al. Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9: 1618-28.
31. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex [published erratum appears in Nature 2010;463:384]. Nature 2009; 462: 182-8.
32. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052-7.